Tezspire 210 MG/1.91 ML pen 1.91ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQT4E
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,758
Award facts
- Contract value 100% obligated
- $19,758.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen auto-injectors, with a ceiling value of $19,758.24. The contract is a firm fixed price delivery order with an ultimate completion date of January 27, 2026, and was awarded on January 5, 2026, without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that provides comprehensive pharmaceutical and medical supply support for military healthcare systems worldwide.
AmerisourceBergen is a major pharmaceutical distributor and critical federal vendor for medical procurement, particularly serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates proven capability in delivering specialized pharmaceuticals, including brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. The SPE2DX contract vehicle under which this award was issued represents a comprehensive global pharmaceutical support mechanism, enabling AmerisourceBergen to supply the broad range of medications and medical commodities necessary to support military healthcare operations. The DLA has indicated plans to establish multiple regional Pharmaceutical Prime Vendor Global Program Generation V contracts, potentially involving at least three contractors, positioning AmerisourceBergen as one of several key pharmaceutical providers for this strategic initiative.
Quick answers
Who was awarded contract SPE2DR26FQT4E?
SPE2DR26FQT4E was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FQT4E worth?
The government has obligated $19,758 on SPE2DR26FQT4E.
Is contract SPE2DR26FQT4E an order under another contract?
Yes. SPE2DR26FQT4E is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQT4E competed?
The extent of competition for SPE2DR26FQT4E was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award